Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CVD Prevalence in HeFH After Statin Treatment

Atherosclerosis; ePub 2019 Feb 12; Perez-Calahorra, et al

Early initiation and prolonged lipid-lowering treatment is associated with reduction in cardiovascular disease (CVD) among patients with heterozygous familial hypercholesterolemia (HeFH), a new study found. The observational, retrospective, multicenter study was designed to establish the current prevalence of CVD in HeFH and to define the impact of high-intensity lipid-lowering (HILLT) on CVD. Odds were estimated using several logistic regression models with progressive adjustment. Researchers found:

  • 1,958 HeFH patients (mean age 49.3 years) were included in the analysis.
  • At inclusion, 295 (15.1%) patients had suffered CVD and 164 (55.6%) had suffered the first event before onset of lipid-lowering treatment.
  • Exposition to treatment associated >10x lower odds for CVD than those individuals native to treatment (OR 0.085).
  • A first CVD event after a mean treatment period of 9.1±7.2 years occurred in 131 of 1,615 (8.1%) HeFH subjects of whom 115 (87.8%) were on HILLT.

Citation:

Perez-Calahorra S, Laclaustra M, Marco-Benedí V, et al. Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia. [Published online ahead of print February 12, 2019]. Atherosclerosis. doi:10.1016/j.atherosclerosis.2019.02.003.

Must Reads in Hypercholesterolemia

CV Events in Statin-Treated Patients with ASCVD, Am J Cardiol; ePub 2019 Mar 8; Chamberlain, et al

Residual Cholesterol Risk in Patients Undergoing PCI, Am J Cardiol; ePub 2019 Mar 9; Guedeney, et al

HeFH & Combined CHL in Premature MI, J Clin Lipidol; ePub 2019 Mar 11; Rallidis, et al

Ischemic Stroke & PAD Risk in HeFH, Angiology; ePub 2019 Mar 14; Akioyamen, et al

LDL-C Level Reduction Treatment Strategies, BMC Cardiovasc Disord; ePub 2019 Mar 11; Császár